InterMune
Acquired
Innovative therapies in pulmonology and fibrotic diseases
- Headquarters
- Palo Alto, California
- Employees
- 201–500
- Founded
- 1995
- Business Model
- B2B
- Website
- intermune.com
About
InterMune was a biotechnology company focused on research, development, and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). They developed Pirfenidone, marketed as Esbriet® in the EU and Canada. The company was acquired by Roche.